T细胞接合剂(TCE)研究进展

陈 珂言
杭州第十四中学国际部

摘要


免疫系统先天具有靶向肿瘤细胞的能力,有证据表明免疫监视在控制肿瘤发生中起着至关重要的作用。免疫肿瘤学方法已进入临床实践,在过去十年中,特别是在T细胞参与的疗法领域取得了巨大进展。基于T细胞的免疫疗法(如T细胞接合剂,TCE)彻底改变了各种癌症的治疗模式,然而,由于肿瘤部位缺乏明显的T细胞浸润,反应率有限仍然是一个主要问题。

关键词


T细胞结合剂;肿瘤相关抗原;T细胞受体

全文:

PDF


参考


[1]Baumeister SH, Freeman GJ,Dranoff G, Sharpe AH.Coinhibitory pathways in immunotherapy for cancer.Annu Rev Immunol.2016;34:539–73.

[2]June CH,Connor RSO,Kawalekar OU,Ghassemi S,Milone MC.CAR T cell immunotherapy for human cancer.Science.2018;359:1361–5.

[3]Goebeler M,Bargou RC.T cell-engaging therapies—BiTEs and beyond.Nat Rev Clin Oncol. 2020;17:418–34.

[4]Sebestyen Z,Prinz I,Dechanet-Merville J, Silva-Santos B,Kuball J.Translating gammadelta (gammadelta)T cells and their receptors into cancer cell therapies.Nat Rev Drug Discov.2020; 19:169–84.

[5]Zhao Y,Aldoss I,Qu C,Crawford JC,Gu Z, Allen EK,et al.Tumor-intrinsic and-extrinsic determinants of response to blinatumomab in adults with BALL.Blood.2021;137:471–84.

[6]Nair-Gupta P,Diem M,Reeves D,Wang W, Schulingkamp R,Sproesser K,et al.A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Adv.2020;4:906–19.

[7]Sharma,P.et al.Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032):a multicentre,open-label,two-stage,multi-arm,phase 1/2 trial.Lancet Oncol. 17,1590–1598(2016).

[8]Kao,H.-F.&Lou,P.-J.Immune checkpoint inhibitors for head and neck squamous cell carcinoma:current landscape and future directions.Head Neck 41,4–18(2019).

[9]Yamamoto K,Venida A,Yano J,Biancur DE, Kakiuchi M,Gupta S,et al.Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.Nature.2020;581:100–5.

[10]Einsele H,Borghaei H,Orlowski RZ, Subklewe M,Roboz GJ,Zugmaier G,et al.The BiTE (bispecific T-cell engager)platform:development and future potential of a targeted immuno-oncology therapy across tumor types.Cancer-Am Cancer Soc.2020;126:3192–201.


Refbacks

  • 当前没有refback。